U.S. Clinical Trials Market Size Worth $36.3 Billion By 2030

U.S. Clinical Trials Market Growth & Trends

The U.S. clinical trials market size is expected to reach USD 36.3 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to expand at a CAGR of 5.4% from 2022 to 2030. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.

The number of people diagnosed with cancer is expected to increase multi-fold in the coming eight years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby boosting the industry’s growth.

The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has also been interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind to minimize risks. Monitoring gadgets, software tools, and mobile phones enable participants to complete the experiment from their homes.

 Request a free sample copy or view the report summary: U.S. Clinical Trials Market Report

U.S. Clinical Trials Market Report Highlights

• Phase III dominated the market with a revenue share of 53.6% in 2021. These trials are more crucial as they involve 300 to 3000 participants and have a longer period of time. Thus, it is the most expensive phase

• The interventional segment accounted for the largest share of 46.0% in 2021

• Based on indication, the oncology segment is anticipated to exhibit the highest CAGR of 5.7% over the analysis timeframe. This growth is due to the growing number of cases of cancer. Thus, a large amount of expenditure is spent on oncology clinical trials

U.S. Clinical Trials Market Segmentation

Grand View Research has segmented the U.S. Clinical Trials Market based on phase, study design, and indication:

U.S. Clinical Trials Phase Outlook (Revenue, USD Million, 2018 - 2030)

• Phase I

• Phase II

• Phase III

• Phase IV

U.S. Clinical Trials Study Design Outlook (Revenue, USD Million, 2018 - 2030)

• Interventional Studies

• Observational Studies

• Expanded Access Studies

U.S. Clinical Trials Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Autoimmune/Inflammation

  • Rheumatoid Arthritis

  • Multiple Sclerosis

  • Osteoarthritis

  • Irritable Bowel Syndrome (IBS)

  • Others

• Pain Management

  • Chronic Pain

  • Acute Pain

• Oncology

  • Blood Cancer

  • Solid Tumors

  • Other

• CNS Conditions

  • Epilepsy

  • Parkinson’s Disease (PD)

  • Huntington’s Disease

  • Stroke

  • Traumatic Brain Injury (TBI)

  • Amyotrophic Lateral Sclerosis (ALS)

  • Muscle Regeneration

  • Others

• Diabetes

• Obesity

• Cardiovascular

• Others

List of Key Players in the U.S. Clinical Trials Market

• Parexel International Corp.

• IQVIA Holdings Inc.

• LabCorp

• Thermo Fisher Scientific (Pharmaceutical Product Development)

• Charles River Laboratory

• ICON plc

• Wuxi AppTec

• Eli Lilly and Company

• SGS SA

• Novo Nordisk A/S

• Clinipace

• Syneos Health Inc.

• Pfizer Inc.